Memphasys (ASX:MEM) Lands Monash IVF Deal, Pushing Felix™ Into Australia’s Fertility Clinics

Key Highlights

• Memphasys signs exclusive 12-month National Supply Agreement with Monash IVF Group
 • Felix™ sperm selection technology set for rollout across Australia’s largest IVF networks
 • Agreement follows recent ARTG regulatory approval in Australia
 • National deployment could extend across 22 Monash IVF clinics after initial implementation phase
 • Recurring cartridge sales create potential long-term revenue stream for Memphasys

Australia’s fertility sector is about to get a new piece of technology in the laboratory.

Memphasys (ASX:MEM) has secured an exclusive National Supply Agreement with Monash IVF Group (ASX:MVF), marking a significant commercial milestone for the reproductive biotechnology company and potentially transforming years of product development into recurring revenue.

The agreement will see Memphasys deploy its Felix™ automated sperm selection system across the Monash IVF network, beginning with an initial rollout phase before a broader national expansion.

For a company that has spent years developing and validating its technology, the deal represents a shift from research and regulatory milestones toward commercial execution.

The announcement follows the recent inclusion of Felix™ on Australia’s Australian Register of Therapeutic Goods (ARTG), removing a key regulatory hurdle and paving the way for domestic commercialisation.

Unlike many early-stage healthcare technologies that struggle to gain adoption after approval, Memphasys has secured a partnership with one of Australia’s largest fertility providers as its first major domestic customer.

Monash IVF is a major force in Australia’s assisted reproductive technology sector, accounting for around 21% of the country’s IVF market. The group reported 12,085 stimulated IVF cycles in 2025 and operates clinics across mainland capital cities.

The agreement arrives at a time when fertility clinics worldwide are searching for ways to improve laboratory outcomes.

Traditional sperm selection methods often rely on centrifugation, a process that uses rapid spinning to isolate sperm cells. While widely used, researchers have long debated whether the process can introduce cellular stress and DNA damage.

Felix™ takes a different approach.

The technology uses a combination of electrophoresis and specialised membrane filtration to identify and isolate healthier sperm cells without centrifugation. The process is designed to be faster, more automated and less disruptive to the cells being selected.

The commercial structure of the agreement is equally noteworthy.

An initial three-month rollout will begin immediately across two designated Monash IVF sites. During this period, embryologists will undergo training while operational performance and clinical metrics are assessed.

Successful implementation would trigger a broader deployment across the remaining Monash IVF network and activate the formal 12-month national supply agreement.

While financial terms have not been disclosed, the model is designed around recurring cartridge sales rather than one-off equipment purchases.

Healthcare technology companies often face uneven revenue profiles when dependent on equipment sales alone. Consumable products such as Felix™ cartridges create the potential for repeat orders and more predictable revenue generation.

The market was still awaiting a full assessment of the deal’s financial implications, with Memphasys shares remaining in a trading halt on Tuesday morning. Prior to the halt, the stock last traded at $0.006, giving the company a market capitalisation of approximately $17.1 million.

Source: MarketIndex 

The announcement also builds on a busy period for the company.

Over the past month, Memphasys has secured a commercialisation agreement in Southeast Asia and announced a 1,000-cartridge order across Middle East and North Africa markets. Together, the developments suggest management is accelerating efforts to establish Felix™ as a global fertility platform rather than a niche Australian product.

Industry trends may also be working in the company’s favour.

Globally, fertility treatment demand continues to rise as couples delay parenthood and healthcare systems increasingly adopt advanced reproductive technologies. Australia alone conducts more than 60,000 IVF cycles annually, creating a sizeable addressable market for innovations that improve laboratory efficiency and clinical outcomes.

The agreement with Monash IVF is particularly important because it follows a multi-site clinical evaluation completed in 2025. Results from that study are expected to be published in the future and could provide further validation for the technology.

Memphasys believes the partnership could also serve as a reference point for international expansion.

Securing one of Australia’s best-known fertility providers gives the company a high-profile commercial case study as it pursues opportunities across Europe, Asia and the Middle East.

While execution risks remain, particularly during the initial rollout period, the announcement marks a notable turning point for the business.

For years, Memphasys was largely viewed as a development-stage biotechnology company. With a commercial agreement now in place and recurring revenue opportunities emerging, the company is beginning to transition from proving its science to proving its business model.

In the fertility industry, where incremental improvements can have life-changing outcomes for patients, that transition could prove just as important as the technology itself.